News|Articles|December 30, 2025

Top 5 respiratory news articles of 2025

Listen

0:00 / 0:00

Key Takeaways

Data textural analysis of lung CT scans can quantify changes linked to declining lung function.
Pulmonary rehabilitation improves quality of life and functional capacity in chronic respiratory conditions.
Nerandomilast shows promise in treating progressive pulmonary fibrosis, following positive results for idiopathic pulmonary fibrosis.
Jascayd, targeting PDE4B, is a newly approved treatment for idiopathic pulmonary fibrosis, affecting fibrosis and the immune system.
Yervoy, a cancer drug, has potential in enhancing lung repair in idiopathic pulmonary fibrosis.

In 2025, respiratory news highlighted advances in lung imaging, expanded support for pulmonary rehabilitation and promising new and repurposed therapies for pulmonary fibrosis.

1. Small changes in lung CT scans linked to declining lung function

Researchers used a data textural analysis to quantify changes seen on high-resolution CT scans.

2. ATS guidelines highlight benefits of pulmonary rehabilitation

Patients with chronic obstructive pulmonary disease, interstitial lung disease and pulmonary hypertension experience improved quality of life and functional capacity as measured in the 6-minute walk distance test.

3. More results for nerandomilast reported by BI, this time for progressive pulmonary fibrosis

Several weeks after reporting positive results for nerandomilast for idiopathic pulmonary fibrosis, Boehringer Ingelheim reported positive results from a similar phase 3 trial assessing its PDE4B inhibitor as a treatment for progressive pulmonary fibrosis.

4. FDA approves a aew option for idiopathic pulmonary fibrosis

Jascayd targets the enzyme PDE4B, which plays a role in the inflammatory process. The new therapy is able to affect both fibrosis and the immune system. It will be available in the next few weeks.

5. Tulane researchers unveil potential new treatment for IPF

An already approved cancer drug, Yervoy (ipilimumab), improved lung repair ability in a study of mice with idiopathic pulmonary fibrosis.

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!